MARKET

NUVB

NUVB

Nuvation Bio Inc
NYSE
5.55
-0.18
-3.06%
Opening 11:26 02/12 EST
OPEN
5.77
PREV CLOSE
5.72
HIGH
5.78
LOW
5.52
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
9.75
52 WEEK LOW
1.540
MARKET CAP
1.90B
P/E (TTM)
-8.6668
1D
5D
1M
3M
1Y
5Y
1D
A Look At Nuvation Bio’s Valuation As Safusidenib SIGMA Trial Advances To Phase 3
Simply Wall St · 1d ago
Forecasting The Future: 9 Analyst Projections For Nuvation Bio
Benzinga · 1d ago
Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush
Dow Jones · 2d ago
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target
Benzinga · 2d ago
Analysts Conflicted on These Healthcare Names: Mettler-Toledo (MTD), Nuvation Bio (NUVB) and Mereo Biopharma Group Plc (MREO)
TipRanks · 2d ago
Nuvation Bio finalizes protocol amendment for study of safusidenib
TipRanks · 3d ago
Nuvation Bio Finalizes Protocol Amendment To Its Current Global SIGMA Trial Of Safusidenib To Also Enroll Non-Pivotal Single-Arm Group
Benzinga · 3d ago
Weekly Report: what happened at NUVB last week (0202-0206)?
Weekly Report · 3d ago
More
About NUVB
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

Webull offers Nuvation Bio Inc stock information, including NYSE: NUVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVB stock methods without spending real money on the virtual paper trading platform.